Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 103Neoplasms, Plasma Cell 11Immunoglobulin Light-chain Amyloidosis 11Recurrence 10Leukemia, Myeloid, Acute 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Paraproteinemias 3Neoplasms 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Waldenstrom Macroglobulinemia 2Smoldering Multiple Myeloma 2Prostatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Plasma Cell 2Hodgkin Disease 2Hematologic Diseases 2Corneal Diseases 2Blood Protein Disorders 2Amyloidosis 2Acute Kidney Injury 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Renal Insufficiency 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Plasmacytoma 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Proteostasis Deficiencies × daratumumab × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡